Bruce D. Jackson

Flexion Therapeutics Inc (NASDAQ: FLXN) is expected to submit NDA for its lead drug candidate, Zilretta, in Q4 this year. Zilretta seems “well positioned to emerge as a breakthrough, best-in-class therapy,” Lake Street Capital Markets’ Bruce D. Jackson said in a report. He...

The FDA has approved Heron Therapeutics Inc’s (NASDAQ: HRTX) lead product Sustol and now the company appears poised to benefit from “existing multi-billion dollar market opportunities,” Lake Street Capital Markets’ Bruce D. Jackson said in a report. He assigned a Buy...

Lake Street Capital Markets initiated coverage on EXACT Sciences Corporation (NASDAQ: EXAS) with a Buy rating and $33.00 price target. Analyst Bruce D. Jackson noted that since “Cologuard has obtained a $492.72 per test reimbursement rate from Medicare, we think there is upside potential...

In a report published Friday, Lake Street Capital Markets analyst Bruce D. Jackson initiated coverage on BioTelemetry (NASDAQ: BEAT) with a Buy rating and $14.00 price target. In the report, Lake Street Capital Markets noted, “BioTelemetry is one of the few publicly-traded, pure-play mobile health...